Chemistry Journals
Cosmos Impact Factor: 0.68
5-Year Journal Impact Factor: 2.684*
Article High Visibility
IC Valve : 73.30
Overview Acta Chimica & Pharmaceutica Indica (ISSN 2277-288X) publishes original peer-reviewed articles. All the research articles are reviewed by senior members of the international academic and scientific community before acceptance and published with advanced adaptable, editable and readable scholarly technology.
The journal is proudly subscribe to the Budapest Initiative and following the recommendations developed by leaders of the Open Access movement, to provide unrestricted, free access to scholarly research globally.
The current Open Access Journal that publishes original research articles as well as review articles on all aspects of fundamental and applied chemistry. Acta Chimica & Pharmaceutica Indica was founded in by and abstracted and indexed in leading scientific databases.It For a complete list, click here.
- Chemical Abstracts (USA)
- CSA Technology Research Database (USA)
- Journal Seek Indian Science Abstracts
The most recent Impact Factor for Acta Chimica & Pharmaceutica Indica is 0.68. It invites research articles in all the fields of Chemistry and Pharmaceutical Sciences which includes the major subject areas like Inorganic, Organic, Physical, Analytical, Biological, Pharmaceutical, Industrial, Environmental, Agro and Soil Chemistry as well as Chemical Physics and Engineering etc.
Submit your manuscripts at [email protected]
*2016 Journal Impact Factor was established by dividing the number of articles published in 2014 and 2015 with the number of times they are cited in 2016 based on Google search and the Scholar Citation Index database. If 'X' is the total number of articles published in 2014 and 2015, and 'Y' is the number of times these articles were cited in indexed journals during 2016 then, impact factor = Y/X
Recently Published Papers
Using nanocarrier systems for Vaccine distribution through nonparenteral administration
Author(s): Imran Saleem
There is a huge drive in the vaccine research field and pharmaceutical industry for effective targeting of antigen presenting cells APCs) to enhance the immune response and for needle-free v..
Short communication, Acta Chim Pharm Indica. 2021 Vol: 11( 2)
Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy
Author(s): Nayara Gusmão Tessarollo
Melanoma is the most aggressive type of skin cancer and has a high lethality. The treatment of cancer has progressed greatly with the advent of immunotherapy and gene therapy, including the ..
Short communication, Acta Chim Pharm Indica. 2021 Vol: 11( 2)
Selection, expansion, and unique pretreatment of allogeneic human natural killer cells with anti-CD38 monoclonal antibody for efficient multiple myeloma treatment
Author(s): Juli R. Bagó
The outcome of patients with multiple myeloma has improved in the past decade as a result of novel therapeutic agents such as immunomodulatory drugs, proteasome inhibitors, monoclonal antibo..
Short communication, Acta Chim Pharm Indica. 2021 Vol: 11( 2)
Poria cocos modulates Th1/Th2 response and attenuates airway inflammation in an ovalbumin-sensitized mouse allergic asthma model
Author(s): Muh-Hwan Su
Poria cocos (Schwein) F.A. Wolf (syn. Wolfiporia cocos) dried sclerotium, called fuling(FL), is an edible, saprophytic fungus commonly used as a tonic and antiaging traditional Chinese medic..
Short communication, Acta Chim Pharm Indica. 2021 Vol: 11( 2)
An SGD goal ???Elimination of Hepatitis by 2030???: hope and hype regarding prophylactic and therapeutic Vaccine
Author(s): Sheikh Mohammad Fazle Akbar
Hepatitis B virus (HBV) has infected about 2 billion people of the world and about 240 million are regarded as patients of chronic hepatitis B (CHB). CHB is progressive and develops cirrhosi..
Short communication, Acta Chim Pharm Indica. 2021 Vol: 11( 2)
